Eleven Biotherapeutics Inc. (NASDAQ:EBIO) major shareholder Ventures Fund Iv L.P Flagship sold 9,700 shares of the company’s stock in a transaction dated Monday, September 19th. The shares were sold at an average price of $3.31, for a total transaction of $32,107.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Ventures Fund Iv L.P Flagship also recently made the following trade(s):

  • On Wednesday, September 21st, Ventures Fund Iv L.P Flagship sold 322,723 shares of Eleven Biotherapeutics stock. The shares were sold at an average price of $3.75, for a total transaction of $1,210,211.25.
  • On Tuesday, September 20th, Ventures Fund Iv L.P Flagship sold 53,917 shares of Eleven Biotherapeutics stock. The shares were sold at an average price of $3.39, for a total transaction of $182,778.63.

Eleven Biotherapeutics Inc. (NASDAQ:EBIO) traded up 3.86% on Wednesday, hitting $3.50. 6,214,655 shares of the stock were exchanged. The company’s market cap is $53.88 million. The company’s 50-day moving average is $4.45 and its 200-day moving average is $2.19. Eleven Biotherapeutics Inc. has a 52 week low of $0.25 and a 52 week high of $5.97.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/eleven-biotherapeutics-inc-ebio-major-shareholder-ventures-fund-iv-l-p-flagship-sells-9700-shares.html

Eleven Biotherapeutics (NASDAQ:EBIO) last issued its quarterly earnings data on Friday, August 12th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter. Eleven Biotherapeutics had a negative net margin of 2,995.34% and a negative return on equity of 207.40%. On average, analysts predict that Eleven Biotherapeutics Inc. will post ($1.75) earnings per share for the current year.

A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp increased its position in shares of Eleven Biotherapeutics by 13.2% in the second quarter. Bank of New York Mellon Corp now owns 67,483 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 7,846 shares during the last quarter. Sabby Management LLC increased its position in shares of Eleven Biotherapeutics by 525.6% in the first quarter. Sabby Management LLC now owns 1,213,984 shares of the biopharmaceutical company’s stock valued at $387,000 after buying an additional 1,019,943 shares during the last quarter. Flagship Ventures Fund IV L.P. acquired a new position in shares of Eleven Biotherapeutics during the first quarter valued at about $469,000. Flagship Ventures Fund 2007 L.P. acquired a new position in shares of Eleven Biotherapeutics during the first quarter valued at about $610,000. Finally, Boxer Capital LLC acquired a new position in shares of Eleven Biotherapeutics during the second quarter valued at about $1,670,000. Hedge funds and other institutional investors own 24.81% of the company’s stock.

Eleven Biotherapeutics Company Profile

Eleven Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye.

5 Day Chart for NASDAQ:EBIO

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.